Please assess the completion status of the following clinical trial:

Trial Title: Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants must be 20 to 65 years of age, inclusive, at the time of signing the ICD.~2. Participants must have four Japanese grandparents born in Japan.~3. Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests (except for TG levels), and 12 lead ECG monitoring.~4. Fasting TG \>= 90 mg/dL at Screening~5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.~6. BMI of 17.5 to 35.0 kg/m2; and a total body weight \>50 kg (110 lb)~7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.~Exclusion Criteria:~1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.~2. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, or HCVAb.~3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~4. History of allergic or anaphylactic reaction.~5. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.~6. Previous administration with an investigational drug within 4 months or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).~7. A positive urine drug test.~8. Screening supine BP \>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is \>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.~9. Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.~10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:~    * AST or ALT level \>=1.25 × ULN;~   * Total bilirubin level \>=1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is=\<ULN.~11. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.~12. Blood donation (excluding plasma donations and platelet donations) of approximately 400 mL within 3 months or \>=200 mL within a month prior to dosing. Additionally, approximately \>=400 mL within 4 months for female participants.~13. History of sensitivity to heparin or heparin induced thrombocytopenia.~14. History of substance abuse within 12 months of the screening visit.~15. Pregnant females; breastfeeding females.~16. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.~17. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Vupanorsen 80 milligram (mg) (Type: EXPERIMENTAL): Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution
- Vupanorsen 160 mg (Type: EXPERIMENTAL): Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution
- Placebo (Type: PLACEBO_COMPARATOR): Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.~Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water.

Based on this trial design, predict the completion outcome and termination type (if applicable).